Expedition Therapeutics’ $115M Series B: General Atlantic Bets on COPD DPP1
General Atlantic led Expedition’s oversubscribed $115M Series B as the biotech dosed the first patient in a global Phase 2 COPD trial of EXPD-101 — a China-sourced NewCo twist.